Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | ALB | P02768 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | TK1 | P04183 | 7/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8920703 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL13286394 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL27505365 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL23485 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL14596607 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL925743 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL29711774 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL14421795 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL22992337 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| Methane SCHEMBL25262791 | 0.99 | TK1 (0.57) | LMNAALBBLMALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129985-A2 | ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4234566-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | BGI Shenzhen (CN) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023113038-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | リードファーマ株式会社 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023086557-A1 | NUCLEOSIDES FOR THE TREATMENT OF DNA VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023004130-A1 | METHODS FOR PREPARING BISPHOSPHOCINS | Lakewood Amedex, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| WO-2022125987-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125984-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022083686-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | 深圳华大生命科学研究院 | 2022-04-28 | — | — | WO | disclosed |
| EP-3169693-B1 | CHIMERIC POLYNUCLEOTIDES | MODERNATX INC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-8137560-B2 | Separation process | GE HEALTHCARE LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| US-8137560-B2 | Separation process | GE HEALTHCARE LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100105888-A1 | SEPARATION PROCESS | GE HEALTHCARE LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20100105888-A1 | SEPARATION PROCESS | GE HEALTHCARE LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7582748-B2 | efficient synthetic route to an optionally protected 1-halo-2-deoxyribose; formation of an alkyl acetal, such as a methyl acetal, of a furanose, such as 2-deoxyribose, optionally protecting the remaining hydroxyl groups of the furanose, reacting the acetal with an acyl halide that forms the acid halide | MICROBIOLOGICA QUIMICA E FARMACEUTICAL LTD. (BR) | 2009-09-01 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7172867-B2 | Methods of testing for allergic diseases, and therapeutic agents for treating same | GENOX RESEARCH, INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7172867-B2 | Methods of testing for allergic diseases, and therapeutic agents for treating same | GENOX RESEARCH, INC. (JP) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | LMNA 2918/4885ALB 2245/4885BLM 1162/4885 |
| US-20100105888-A1 | SEPARATION PROCESS | PAICS, EPHX2, SAMHD1 | LMNA 2414/4885ALB 4525/4885BLM 1177/4885 |
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | MAPT, GAP43, RNMT | LMNA 1392/4885ALB 4034/4885BLM 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.